The promise of adoptive cellular immunotherapies in hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The promise of adoptive cellular immunotherapies in hepatocellular carcinoma

Published:2019-10-13 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Hendrickson Peter G.¹,Olson Michael²,Luetkens Tim²,Weston Siani¹,Han Tiffany³,Atanackovic Djordje²,Fine Gabriel C.¹

Affiliation:

1. Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT, USA

2. Hematology and Hematologic Malignancies, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT, USA

3. Department of Radiology, Norwalk Hospital, Norwalk, CT, USA

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2019.1673129

Reference63 articles.

1. Cancer statistics, 2019

2. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States

3. Hepatocellular carcinoma

4. Therapeutic advances for patients with intermediate hepatocellular carcinoma

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors;Journal for ImmunoTherapy of Cancer;2024-07

2. Insights in Molecular Therapies for Hepatocellular Carcinoma;Cancers;2024-05-10

3. Role of immunotherapies and stem cell therapy in the management of liver cancer: A comprehensive review;International Immunopharmacology;2024-05

4. Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity;Hepatology International;2023-10-12

5. Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma;Cancer Immunology, Immunotherapy;2023-09-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3